NCT05853575 2026-03-27
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Active not recruiting
Mirati Therapeutics Inc.
Hoffmann-La Roche
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Verastem, Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.